Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Clin Exp Oncol Vol: 6 Issue: 3

Anti Adeno-Associated Virus 2 (AAV) Antibody Profile in Ovarian Cancer Ascitic Fluid: Implications for AAV Intraperitoneal Gene Therapy

Joanna Skubis-Zegadło1*, Magdalena Kowalska2, Beata Śpiewankiewicz4, Wacław Śmiertka3, Krzysztof Gawrychowski1 and Maciej Małecki1

1Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland

2Department of Gynecologic Oncology, Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland

3Department of Oncology, National Institute of Oncology, Warsaw, Poland

4Department of Gynecological Oncology and Oncology, Medicover Hospital, Warsaw, Poland

*Corresponding Author : Joanna Skubis-Zegadło
Department of Applied Pharmacy and Bioengineering, Medical University of Warsaw, ul. Banacha 1, 02-091 Warsaw, Poland
Tel: +48 22 57 20 977
E-mail: [email protected]

Received: February 15, 2017 Accepted: February 27, 2017 Published: March 06, 2017

Citation: Skubis-Zegadło J, Kowalska M, Śpiewankiewicz B, Śmiertka W, Gawrychowski K, et al. (2017) Anti Adeno-Associated Virus 2 (AAV) Antibody Profile in Ovarian Cancer Ascitic Fluid: Implications for AAV Intraperitoneal Gene Therapy. J Clin Exp Oncol 6:3. doi: 10.4172/2324-9110.1000183.

Abstract

Objective: Recombinant adeno-associated virus (rAAV) type 2 is a common vector used in gene therapy. However, the presence of anti-AAV2 neutralizing antibodies or other neutralizing factors can significantly limit effective transduction. Intraperitoneal gene therapy could enable local delivery of the target gene directly to ovarian cancer cells. Until now, there have been no reports on the presence of anti-AAV antibodies in ascitic fluid, which might limit the effectiveness of rAAV as a candidate vector for intraperitoneal gene therapy. Thus, the characterization of the preexisting neutralization antibodies in ascitic fluid will provide insight into successful intraperitoneal gene therapy.

Methods: The study was conducted on 23 ascitic fluid samples obtained from women with stage 3 and 4 ovarian cancer. The samples were collected to determine the presence of anti-AAV antibodies with ELISA test and the presence of neutralizing antibodies with neutralizing assay.

Results: Our results indicate that anti-rAAV antibodies are present in 70%, whereas neutralizing factors/antibodies are present in 78% of analyzed ascitic fluid samples. This correlation provides evidence for the presence of additional, different from antibodies, currently unknown factors in ascites, which are able to inhibit AAV2 infection in the absence of anti-AAV antibodies.

Conclusion: The presence of neutralizing antibodies against rAAV or other neutralizing factors in ascitic fluid should be taken into account during intraperitoneal gene therapy, because they might limit effective intraperitoneal gene therapy with rAAV as a vector.

Keywords: Adeno-Associated Virus (AAV); Ascites; Ovarian cancer; Gene therapy; Neutralizing antibodies; Anti-AAV antibodies

Track Your Manuscript

Share This Page

Media Partners